Allosteric PAR1 Modulators for Selective Antiplatelet Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiplatelet agents often fail to achieve a potent antiplatelet effect without causing hemorrhagic complications, and there is a need for more specific and effective allosteric modulators that can selectively inhibit protease-activated receptor 1 (PAR1) without affecting PAR4, to treat thrombotic and vascular disorders.
Innovation Solution
Development of compounds of specific chemical formulas that act as allosteric modulators, selectively inhibiting PAR1-mediated platelet activation and thrombus formation by binding at a site separate from the ligand binding site, inducing a conformational change in the receptor, thereby reducing platelet activation and aggregation without affecting PAR4 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiplatelet agents are used to achieve potent antiplatelet effect, then platelet activation is inhibited, but hemorrhagic complications occur
Solution Approach 1:
The patent applies local quality by designing compounds that selectively target PAR1 receptor with specific structural features (cyclic amine moiety, aromatic ring, carbonyl group) to achieve localized inhibition at the thrombin-receptor interface while sparing other platelet activation pathways and coagulation factors, thereby reducing hemorrhagic risk
Solution Approach 2:
The patent employs parameter changes by optimizing molecular parameters of the compounds (molecular weight, lipophilicity, structural configuration) to achieve optimal binding affinity for PAR1 while maintaining selective inhibition, allowing potent antiplatelet effect at lower doses with reduced off-target effects
2Reliability
If allosteric modulators are developed to selectively inhibit PAR1, then specificity is improved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the allosteric modulator compound into distinct functional segments: a cyclic amine moiety for PAR1 binding, an aromatic ring for structural stability, and a carbonyl group for hydrogen bonding, allowing systematic optimization of selectivity while managing complexity
Solution Approach 2:
The patent uses the allosteric modulator compound as an intermediary that binds to a site distinct from the orthosteric ligand binding site on PAR1, inducing conformational changes that selectively inhibit PAR1-mediated platelet activation without competing with natural ligands, thereby achieving high selectivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit PAR1-mediated platelet activation and thrombus formation, demonstrating a high selectivity for PAR1 over PAR4, reducing platelet accumulation and fibrin generation at vascular injury sites, while maintaining stability and efficacy in human plasma.
Implementation Method 1
Allosteric modulators can bind GPCRs outside of the ligand binding site and induce a conformational change in the receptor
Data Source
AI summary
The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof.